Prospective treatment in carnitine-acylcarnitine translocase deficiency
- PMID: 17508264
- DOI: 10.1007/s10545-007-0518-x
Prospective treatment in carnitine-acylcarnitine translocase deficiency
Abstract
Carnitine-acylcarnitine translocase (CACT) deficiency is a rare disorder that results in long-chain fatty acids being unavailable for mitochondrial beta-oxidation and ketogenesis. It can present in the neonatal period or infancy with a severe clinical form, typically with convulsions, hypothermia, encephalopathy, cardiomyopathy and liver dysfunction, or with a milder phenotype with episodes of hypoglycaemia and hyperammonaemia during intercurrent illness. Investigations show hypoketonaemia, intermittent dicarboxyluria and hypocarnitinaemia with grossly elevated acylcarnitines. Enzyme assay or DNA analysis confirms the diagnosis. The severe phenotype results in severe disability or death. The less severe phenotype can also cause significant disability secondary to hypoglycaemia and/or hyperammonaemia at presentation. We report the outcome of two siblings with CACT deficiency. The index patient presented at the age of 2 months during a respiratory illness with hypoglycaemia, hyperammonaemia and cardiorespiratory collapse. Acylcarnitine profiles showed decreased free carnitine but striking elevations of long-chain acylcarnitines. Urine organic acids showed dicarboxylic aciduria. Fatty acid oxidation studies showed reduced oleate and myristate oxidation. His acylcarnitine profile normalized after he was started on a medium-chain triglyceride (MCT) low-fat diet and carnitine supplementation. Low CACT activity on enzyme assay confirmed the diagnosis. He has resulting profound developmental delay and epilepsy. The sibling was prospectively treated with a low-fat MCT diet and carnitine supplementation. Acylcarnitine profile at birth also showed elevated long-chain acylcarnitines. Fatty acid oxidation studies confirmed the diagnosis. To date he has normal development and has not had any significant periods of hypoglycaemia or hyperammonaemia.
Similar articles
-
Carnitine-Acylcarnitine Translocase Deficiency.2022 Jul 21. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2022 Jul 21. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 35862567 Free Books & Documents. Review.
-
Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation.Am J Med Genet A. 2004 Apr 15;126A(2):150-5. doi: 10.1002/ajmg.a.20573. Am J Med Genet A. 2004. PMID: 15057979
-
Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects.Mol Aspects Med. 2004 Oct-Dec;25(5-6):521-32. doi: 10.1016/j.mam.2004.06.007. Mol Aspects Med. 2004. PMID: 15363639 Review.
-
Carnitine-acylcarnitine translocase deficiency: identification of a novel molecular defect in a Bedouin patient.J Inherit Metab Dis. 2004;27(2):267-73. doi: 10.1023/B:BOLI.0000028780.01670.61. J Inherit Metab Dis. 2004. PMID: 15159657 Review.
-
Carnitine-acylcarnitine translocase deficiency.Am J Med Sci. 1999 Jul;318(1):22-7. doi: 10.1097/00000441-199907000-00004. Am J Med Sci. 1999. PMID: 10408757 Review.
Cited by
-
Mass Spectrometry-Based Metabolomics Revealed Effects of Metronidazole on Giardia duodenalis.Pharmaceuticals (Basel). 2023 Mar 7;16(3):408. doi: 10.3390/ph16030408. Pharmaceuticals (Basel). 2023. PMID: 36986506 Free PMC article.
-
One potential hotspot SLC25A20 gene variants in Chinese patients with carnitine-acylcarnitine translocase deficiency.Front Pediatr. 2022 Nov 7;10:1029004. doi: 10.3389/fped.2022.1029004. eCollection 2022. Front Pediatr. 2022. PMID: 36419912 Free PMC article.
-
Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.Metabolomics. 2022 Jul 11;18(7):50. doi: 10.1007/s11306-022-01909-4. Metabolomics. 2022. PMID: 35819637
-
The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.Front Pharmacol. 2020 Mar 24;11:351. doi: 10.3389/fphar.2020.00351. eCollection 2020. Front Pharmacol. 2020. PMID: 32265720 Free PMC article. Review.
-
Fatty acid oxidation disorders.Ann Transl Med. 2018 Dec;6(24):473. doi: 10.21037/atm.2018.10.57. Ann Transl Med. 2018. PMID: 30740404 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical